Literature DB >> 19380328

Growth hormone resistance in severe heart failure resolves after cardiac transplantation.

Lars H Lund1, Pamela Freda, Jill J Williams, John J LaManca, Thierry H LeJemtel, Donna M Mancini.   

Abstract

AIMS: Severe heart failure (HF) is associated with cachexia; this is often reversed post cardiac transplantation (HTx) with frequent development of obesity. Growth hormone (GH) resistance is common in HF and may contribute to cachexia. Whether GH resistance resolves post HTx is unknown. We aimed to confirm that HF is associated with GH resistance and to test the hypothesis that GH resistance resolves post HTx. METHODS AND
RESULTS: We measured GH, insulin-like growth factor-1 (IGF-1), and body composition in 10 HF patients awaiting HTx, in 18 patients 11 +/- 8 months post HTx, and seven controls. Body mass index was 23.5 +/- 3.2 in HF patients and 29.3 +/- 5.7 post HTx. HTx patients had gained 14 +/- 8 kg since HTx. GH was elevated in HF (control: 0.21 +/- 0.25; HF: 1.13 +/- 1.19; HTx: 0.11 +/- 0.13 ng/mL; P < 0.007), while IGF-1 was higher in HTx (control: 114 +/- 57; HF: 94 +/- 52; HTx: 190 +/- 106 ng/mL; P < 0.02). HTx had higher total body and abdominal fat %.
CONCLUSION: GH resistance is present in severe HF and resolves post HTx. These findings should be confirmed through larger trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380328      PMCID: PMC2671964          DOI: 10.1093/eurjhf/hfp044

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  12 in total

1.  Excessive weight gain in cardiac transplant recipients.

Authors:  Jill J Williams; Lars H Lund; John LaManca; Chandra Kunavarapu; David J Cohen; Stanley Heshka; Steven B Heymsfield; Donna M Mancini
Journal:  J Heart Lung Transplant       Date:  2005-11-17       Impact factor: 10.247

2.  Cardiomyocyte apoptosis is related to left ventricular dysfunction and remodelling in dilated cardiomyopathy, but is not affected by growth hormone treatment.

Authors:  Waltraut Ibe; Antti Saraste; Stephan Lindemann; Stephanie Bruder; Michael Buerke; Harald Darius; Kari Pulkki; Liisa-Maria Voipio-Pulkki
Journal:  Eur J Heart Fail       Date:  2006-08-04       Impact factor: 15.534

3.  Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting.

Authors:  Yao-Hua Song; Yangxin Li; Jie Du; William E Mitch; Nadia Rosenthal; Patrick Delafontaine
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

4.  Growth hormone alone or combined with metoprolol preserves cardiac function after myocardial infarction in rats.

Authors:  E Bollano; C H Bergh; C Kjellström; E Omerovic; V Kujacic; K Caidahl; B A Bengtsson; F Waagstein; J Isgaard
Journal:  Eur J Heart Fail       Date:  2001-12       Impact factor: 15.534

5.  Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone.

Authors:  S D Anker; M Volterrani; C D Pflaum; C J Strasburger; K J Osterziel; W Doehner; M B Ranke; P A Poole-Wilson; A Giustina; R Dietz; A J Coats
Journal:  J Am Coll Cardiol       Date:  2001-08       Impact factor: 24.094

6.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia.

Authors:  S D Anker; T P Chua; P Ponikowski; D Harrington; J W Swan; W J Kox; P A Poole-Wilson; A J Coats
Journal:  Circulation       Date:  1997-07-15       Impact factor: 29.690

7.  Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure.

Authors:  Rainer Hambrecht; Paul Christian Schulze; Stephan Gielen; Axel Linke; Sven Möbius-Winkler; Jiangtao Yu; J ürgen Kratzsch J; Gerhard Baldauf; Martin W Busse; Andreas Schubert; Volker Adams; Gerhard Schuler
Journal:  J Am Coll Cardiol       Date:  2002-04-03       Impact factor: 24.094

8.  Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.

Authors:  Stuart J Pocock; John J V McMurray; Joanna Dobson; Salim Yusuf; Christopher B Granger; Eric L Michelson; Jan Ostergren; Marc A Pfeffer; Scott D Solomon; Stefan D Anker; Karl B Swedberg
Journal:  Eur Heart J       Date:  2008-09-26       Impact factor: 29.983

Review 9.  Alteration of somatotropic function by proinflammatory cytokines.

Authors:  R A Frost; C H Lang
Journal:  J Anim Sci       Date:  2004       Impact factor: 3.159

Review 10.  Growth hormone resistance in chronic heart failure and its therapeutic implications.

Authors:  Mariantonietta Cicoira; Paul R Kalra; Stefan D Anker
Journal:  J Card Fail       Date:  2003-06       Impact factor: 5.712

View more
  8 in total

1.  Leptin resistance after heart transplantation.

Authors:  Lars H Lund; Pamela Freda; Jill J Williams; John J LaManca; Thierry H LeJemtel; Donna M Mancini
Journal:  Eur J Heart Fail       Date:  2010-03-01       Impact factor: 15.534

2.  Acylation of ghrelin is increased in heart failure and decreases post heart transplantation.

Authors:  Stanislava Zabarovskaja; Pamela Freda; Jill J Williams; Chandra Kunavarapu; John Lamanca; Donna Mancini; Lars H Lund
Journal:  Scand Cardiovasc J       Date:  2014-09-18       Impact factor: 1.589

Review 3.  Skeletal muscle protein metabolism in human heart failure.

Authors:  Damien M Callahan; Michael J Toth
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2013-01       Impact factor: 4.294

4.  Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation.

Authors:  Lars H Lund; Jill J Williams; Pamela Freda; John J LaManca; Thierry H LeJemtel; Donna M Mancini
Journal:  Eur J Heart Fail       Date:  2009-06-25       Impact factor: 15.534

5.  Body composition and maximal exercise capacity after heart transplantation.

Authors:  Julien Regamey; Pierre Monney; Patrick Yerly; Lucie Favre; Matthias Kirsch; Piergiorgio Tozzi; Olivier Lamy; Roger Hullin
Journal:  ESC Heart Fail       Date:  2021-12-02

6.  The Value of IGF-1 and IGFBP-1 in Patients With Heart Failure With Reduced, Mid-range, and Preserved Ejection Fraction.

Authors:  Shaohua Guo; Mengqi Gong; Gary Tse; Guangping Li; Kang-Yin Chen; Tong Liu
Journal:  Front Cardiovasc Med       Date:  2022-01-21

Review 7.  Frailty in Advanced Heart Failure: A Consequence of Aging or a Separate Entity?

Authors:  Deena S Goldwater; Sean P Pinney
Journal:  Clin Med Insights Cardiol       Date:  2015-07-13

8.  Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure.

Authors:  Tuba Khawaja; Aalap Chokshi; Ruiping Ji; Tomoko S Kato; Katherine Xu; Cynthia Zizola; Christina Wu; Daniel E Forman; Takeyoshi Ota; Peter Kennel; Hiroo Takayama; Yoshifumi Naka; Isaac George; Donna Mancini; Christian P Schulze
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-08-07       Impact factor: 12.910

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.